Access to autologous cellular immunotherapies in Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022.
2025 · 4th Quarter (Oct 1 - Dec 31)
DENDREON PHARMACEUTICALS LLC
Filed by THE MCMANUS GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $30,000.00
- Expenses
- Not reported
- Registrant
- THE MCMANUS GROUP
- Filing UUID
- 89f4dfe4-086e-4454-b6a2-90793b2b68a7
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to the Department of Veterans Affairs National Oncology Program's Prostate Cancer Oncology Clinical Pathway.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.